INTRODUCTION
Asthma, a chronic airway disease characterized by recurrent airway narrowing, is associated with reduced physical activity levels (7, 32) . Physical activity/exercise training is important for disease management in asthma as it reduces airway inflammation (22) and improves asthma symptoms (22) . Physical activity avoidance in asthma is suggested to be due to intensified perceived breathlessness (i.e., dyspnea) during exertion (21) . However, traditional markers of ventilation during exercise, such as peak minute ventilation (V E ), breathing reserve (V E /maximal voluntary ventilation), and ventilatory equivalents for oxygen (V E /V O 2 ) and carbon dioxide (V E /V CO 2 ), do not differ between controlled patients with asthma and healthy individuals (4, 30) and do not explain the increased perceived dyspnea in asthma.
Expiratory flow limitation (EFL) occurs when the tidal breath increases to the extent where it becomes limited by the maximal expiratory flow of the lungs and can be seen during exercise as the tidal breath overlapping with the outer boarder of the maximal flow volume loop (11) . EFL is believed to result in an upward shift toward higher operating lung volumes [i.e., reduced inspiratory capacity (IC) and inspiratory reserve volume (IRV)] and the development of dynamic lung hyperinflation (11) . The occurrence of high operating lung volumes has been linked to intensified dyspnea during bronchoconstriction at rest in asthma (17, 18) and been shown to be a powerful determinant of dyspnea in chronic obstructive pulmonary disease (16, 25, 27) . Importantly, during constant workload exercise, patients with asthma with a critically low IRV report greater dyspnea than patients with asthma with larger IRV (15) , but it is unknown if the reduction in exertional IRV during exercise explains the increased sensation of dyspnea in asthma as compared with healthy controls.
Short-acting ␤ 2 -agonists are currently used as the mainstream treatment for acute asthma symptoms, and their usage has been implemented in asthma guidelines worldwide as part of standard asthma management (1) . Many patients with asthma have mild airflow obstruction at baseline which is reversed with a ␤ 2 -agonists, and while most patients with asthma do not experience symptoms of dyspnea at rest, dyspnea typically develops during higher intensity physical activity. Although prescribed liberally, it is not well known how short-acting ␤ 2 -agonists affect operating lung volumes, and thus sensory responses, to exercise in asthma.
The purpose of this study was to better our understanding of the mechanisms of dyspnea in patients with asthma. It was hypothesized that patients with asthma would breathe at higher operating lung volumes compared with healthy controls, as demonstrated by a reduced IC and IRV during exercise, and that this would be associated with the increased sensation of dyspnea in patients with asthma. Further, it was proposed that the administration of the ␤ 2 -agonists salbutamol would prevent exercise-induced reductions in IC or IRV and, as a result, reduce exertional dyspnea in asthma.
MATERIALS AND METHODS
Study subjects. This study was approved by the University of Alberta Ethics Board, and all subjects were required to sign informed consent before participating. Asthma (n ϭ 16) was confirmed if the participant had a clinical history of asthma and met at least one of the following criteria: 1) Ն200 ml and 12% improvement in forced expiratory volume in one second (FEV 1) following ␤2-agonist administration, 2) Ն10% reduction in FEV 1 following exercise, or 3) a positive bronchial challenge test (1, 19) at the time of the study or within the previous year. Control subjects (n ϭ 16) all had no clinical history of asthma, normal lung function, no reversibility with ␤ 2-agonists, and no significant reduction in FEV1 following exercise. All participants were free from known cardiovascular disease or lung disease, other than asthma. Patients with asthma were requested to withhold long-acting controller medication for a minimum of 48 h and short-acting reliever medication for 8 h before each study visit. All participants were asked to withhold caffeine, heavy exercise, and alcohol on the days of the study.
Study design. Each participant reported to the laboratory on 2 different days, at least 48 h apart, for this randomized case-control crossover study. Asthma control was evaluated according to the asthma control questionnaire (12, 13) , and a physical activity readiness questionnaire was used to screen for known contraindications to exercise. In addition, medical history and demographics were obtained from all participants before any physiological testing. On one of the testing days, a complete pulmonary function test (20, 24, 33) followed by an incremental exercise test to exhaustion was completed. On the second day, the participants completed only spirometry and airway resistance testing at baseline, followed by a second incremental exercise test to exhaustion. In random order on one of the days, airway reversibility was assessed during the spirometry testing following 400 g of salbutamol (Ventolin, Glaxo-SmithKline, Mississauga, Canada) administered 20 min before the start of exercise. Data from this day were also used to evaluate the potential impact of salbutamol on operating lung volumes and dyspnea during exercise. The subjects were not blinded to salbutamol administration.
Pulmonary function testing. Baseline spirometry, lung volume, and diffusion capacity were measured as per current guidelines (20, 24, 33) on the Vmax Spectra V29System (SensorMedics, Yorba Linda, CA). Additionally, airway resistance was measured using the forced oscillation technique, impulse oscillometry (CareFusion, Yorba Linda, CA) (29) .
Incremental exercise test. A cardiopulmonary exercise test was performed on a stationary cycle ergometer (Ergoselect 200, Ergoline, Bitz, Germany) starting at steady-state rest, followed by 25-W stepwise increases in workload every 2 min until volitional exhaustion. Metabolic breath-by-breath data were recorded (Vmax Spectra V29System; SensorMedics) continuously throughout the test.
IC measurements were completed during the last 30 s of each stage to calculate operating lung volumes, and the IRV was calculated as IC Ϫ tidal volume (V T), expressed as a percentage of total lung capacity. EFL was evaluated at each workload using the IC and spirometry data by determining the percentage at which the VT curve overlapped with the maximal flow-volume curve obtained at baseline of the same testing day (11) . Dyspnea was assessed according to the modified Borg scale (0 -10) for perceived intensity of breathlessness (2) during the last 20 s of each exercise workload and at peak exercise. An average of the ventilatory and metabolic data obtained over 30 s at the start of the second minute of each stage was used for analysis (10) .
Statistical analysis. Baseline demographics and lung function were compared between patients with asthma and controls using unpaired Student's t-tests for continuous variables and the chi-square test for discontinuous variables. Spirometry values were compared between disease conditions (factor 1) and before and after the use of bronchodilator (factor 2, repeated factor) with 2-way repeated measures Values are expressed as mean Ϯ standard deviation. ACQ, asthma control questionnaire; ICS, inhaled corticosteroid; LABA, long-acting bronchodilator; SABA, short-acting ␤2-agonist. *P Ͻ 0.05 between disease conditions. Values are expressed as mean Ϯ standard deviation. BD, bronchodilator; CPET, cardiopulmonary exercise test; DLCO, diffusion capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; IC, inspiratory capacity; R5, total respiratory resistance; R20, proximal respiratory resistance; RV, residual volume; TLC, total lung capacity. *P Ͻ 0.05 between disease conditions pre-BD; **P Ͻ 0.05 within condition compared with prebronchodilator.
ANOVA. Remaining pulmonary function parameters were evaluated between groups using Student's unpaired t-test. Three-way complex mixed design ANOVAs were used to assess the interactions between disease condition (between-group factor), bronchodilator usage (repeated factor 1) and sensory (dyspnea and leg discomfort), ventilatory, and metabolic parameters at baseline, 50 W, 75 W, 100 W, 125 W, and individual peak workload (repeated factor 2). Significant interactions were further evaluated with multiple comparisons (group averages compared at each workload and peak exercise) corrected with Bonferroni's post hoc test. Further comparisons were made between disease conditions (bronchodilator usage not taken into consideration because of lack of effect) and dyspnea in relation to operating lung volumes at the same workloads as above with a two-way repeated measures ANOVA, followed by Bonferroni-corrected multiple comparisons (group averages compared at each workload and peak exercise). Graphs were plotted using Sigma plot (version 13.0, Systat Software Inc., San Jose, CA), and statistical tests were performed using SPSS Statistical software v. 24.0.0.0 (IBM Corp, Armonk, NY). Statistical significance was set to P Ͻ 0.05 a priori.
RESULTS

Subjects.
Sixteen patients with asthma and sixteen patients without asthma (controls) participated in the study and were group-matched for age, sex, and fitness [% rate of peak oxygen volume uptake (V O 2peak ) predicted] ( Table 1 ). All participants were nonsmokers, and the patients with asthma were classified as controlled (68.8%) or partly controlled (31.3%) as per the asthma control questionnaire (12, 13) .
Ventilatory responses to salbutamol at baseline and during exercise. The differences in FEV 1 seen at baseline between patients with asthma and controls were attenuated with 400 g salbutamol ( Table 2 ). Salbutamol administration did not affect V O 2peak , IC, IRV, dyspnea, or the ventilatory responses to incremental exercise in either patients with asthma or controls ( Figs. 1 and 2 ), nor did it affect peak EFL ( Table 3 ). As there was no effect of salbutamol, all further comparisons between . Ventilatory responses to exercise in patients with asthma and controls with and without salbutamol. Graphs display means Ϯ standard error of mean. *P Ͻ 0.05 between asthma and controls. BD, bronchodilator; fR, respiratory frequency; V E, minute ventilation; V E/V CO2, ventilatory equivalent to carbon dioxide production; V O2, oxygen uptake; VT, tidal volume.
asthma and controls are reported from the nonsalbutamol condition.
Ventilatory and metabolic responses to exercise. Patients with asthma and controls showed similar responses in V O 2 and V E/V CO 2 at both submaximal and peak workloads ( Fig. 1 and Table 3 ). Ventilation was similar between groups throughout exercise; however, patients with asthma adopted a more rapid and shallow breathing pattern at peak exercise, as demonstrated by a lower V T and greater breathing frequency (f R ) (Fig.  1) . As seen in Fig. 3 , both IC and IRV were lower in patients with asthma than controls at all exercise workloads. Only three of the controls and four of the patients with asthma developed dynamic hyperinflation, defined as a reduction of 150 ml compared with rest (26) , and the occurrence of dynamic hyperinflation with exercise was the same on both the salbutamol and the nonbronchodilator day.
Dyspnea and ventilatory responses during exercise. Patients with asthma reported greater dyspnea at submaximal workloads as compared with controls; however, peak dyspnea was not different between patients with asthma and controls (Fig.  1) . EFL did not occur in either group until peak exercise, where no differences were seen between groups (Tables 3 and 4) . To examine the mechanism for the elevated exertional dyspnea in asthma, dyspnea was graphed relative to V E, VT, f R , and IRV (Fig. 4) . While the submaximal between-group differences in dyspnea are evident when plotted against V E, VT, and f R , the differences disappeared when dyspnea was expressed relative to IRV. The superimposition of dyspnea relative to IRV suggests that the low IRV in asthma likely explains why people with asthma experience elevated exertional dyspnea.
DISCUSSION
This study evaluated the ventilatory and sensory responses to incremental exercise in patients with asthma and controls. As a secondary purpose, the impact of salbutamol on dyspnea during exercise was evaluated. The main findings of this study are twofold. First, exertional dyspnea was higher in patients with asthma as compared with controls, secondarily to a lower IRV. The increased dyspnea and higher operating lung volumes in patients with asthma were not due to greater occurrence or magnitude of EFL. These data suggest that higher operating lung volumes, seen as reduced IC and IRV relative to controls, are key contributors to exertional dyspnea in asthma. Second, while improving airflow limitation in patients with asthma, an acute ␤ 2 -agonist did not change breathing pattern, Values are expressed as mean Ϯ standard deviation. BD, bronchodilator; EFL, expiratory flow limitation; fR, respiratory frequency; HR, heart rate; PETCO2, partial pressure of end-tidal carbon dioxide; RQ, respiratory quote; V E, minute ventilation; V O2, rate of volume of oxygen uptake; VT, tidal volume. *P Ͻ 0.05 between disease conditions. EFL, IC, IRV, or dyspnea responses to incremental exercise in either patients with asthma or controls.
Similar to previous research (4, 30), we did not find group differences in traditional markers of ventilatory efficiency (elevated V E/V CO 2 ) or peak ventilation during exercise. Despite this, and in contrast to previous studies (4), the patients with asthma in the current study reported significantly higher degrees of dyspnea at submaximal work rates compared with controls ( Fig. 1) . IRV has previously been reported to be a main determinant of dyspnea in chronic obstructive pulmonary disease (16, 25, 27) , but the relationship between operating lung volumes and exertional dyspnea in asthma has thus far been unknown. Previous studies suggest that inspiratory effort is a main contributor to breathlessness during the onset of asthma-associated bronchoconstriction at rest (17, 18) , and the sensation of breathlessness and increased inspiratory effort link well with low resting IC measures (18) . However, these conclusions are limited to resting conditions, and it is unknown how applicable the results are to exercise. This study expanded on results from the resting studies by evaluating breathing patterns, operating lung volumes, and dyspnea during exercise in asthma. While patients with asthma did not show evidence of dynamic hyperinflation with exercise, the elevated operating lung volumes at rest and throughout exercise likely resulted in a mechanical constraint on V T expansion with increasing exercise intensity, which resulted in patients with asthma adopting a more rapid and shallow breathing pattern (Fig. 1) . The reduced IRV positioned V T closer to total lung capacity, which increases the elastic loading of the functionally weakened inspiratory muscles (9, 28) . Combined with the accompanying tachypnea, it is logical to suggest that the mechanical abnormalities present in patients with asthma may have led to a disparity between respiratory effort and simultaneous lung volume expansion (i.e., neuromechanical uncoupling) and may help to explain the mechanism behind the increased perceived dyspnea in patients with asthma (9) . When dyspnea was plotted against IRV, there was a complete superimposition of the graphs in patients with asthma and controls, suggesting that the EELV, end-expiratory lung volume; EFL, expiratory flow limitation; EILV, end-inspiratory lung volume; fR, breathing frequency; IC, inspiratory capacity; IRV, inspiratory reserve volume; RQ, respiratory quotient; TLC, total lung volume; VCO2, rate of carbon dioxide production; V E, minute ventilation; V O2, rate of oxygen volume uptake; VT, tidal volume. *P Ͻ 0.05 between control and asthma at corresponding intensity. increased perceived dyspnea is secondary to reduced IRV during incremental exercise. Critically low IRV values during constant workload exercise have also previously been linked to increased dyspnea in asthma (15) , and our findings provide additional support demonstrating a link between IRV and dyspnea in patients with asthma.
Lower physical activity levels in asthma are in part due to a fear of increased symptoms sensations, such as dyspnea, following exercise (21) . Previous work has shown that when matched for physical activity levels, mild sedentary patients with asthma and sedentary controls do not differ in their sensation of dyspnea during incremental exercise (4). While physical activity levels were not measured in the current study, aerobic fitness and physical activity are closely related (3), and our groups were well matched for aerobic fitness (control: 47.4 Ϯ 8.4 vs. asthma: 48.4 Ϯ 6.9 ml·kg Ϫ1 ·min Ϫ1 ; Table 3 ). Despite being fitness-matched, patients with asthma in the current study reported significantly greater dyspnea during exercise as compared with controls, with a maximal difference of 1.6 Borg units observed at 125 W. Our subjects achieved on average a 50% higher relative V O 2peak (i.e., 17 ml·kg Ϫ1 ·min
Ϫ1
) than what was reported in the previous study (4) , and the peak ventilation among the patients with asthma in the current study was 59% (45 l/min) higher than previously reported, suggesting that the difference seen in dyspnea may appear at higher ventilatory rates. However, the V E at the corresponding workloads where the discrepancy in dyspnea between patients with asthma and controls becomes apparent (75, 100, and 125 W) are well within the range of the obtained V E of the patients with asthma in the previous study (~76 l/min). It is thus reasonable to argue that differences in dyspnea between the two studies are not due to aerobic fitness, and further research on other factors, such as asthma severity and control, is warranted to assess why some groups of patients with asthma, but not others, experience increased exertional dyspnea.
Salbutamol is a commonly prescribed short-acting bronchodilator that acts on the ␤ 2 -adrenoceptors on the bronchial smooth muscles and thereby causes relaxation and opens constricted airways. While salbutamol is thought to prevent exercise-induced bronchoconstriction (EIB) among susceptible individuals or relieve asthma symptoms brought on by physical activity (1, 19) , this study evaluated the direct impact of using salbutamol on exertional dyspnea in asthma. As seen in Table  3 , salbutamol did not significantly reduce the degree of EFL in patients with asthma, and likewise, there were no differences in operating lung volumes following salbutamol (data not shown). It can be speculated that the higher operating lung volumes in asthma may be a response to the higher baseline airway resistance and a compensatory response to limit the increased resistive work of breathing. The lack of effect of salbutamol on operating lung volumes during higher intensity exercise in asthma likely explains why dyspnea in patients with asthma does not improve with salbutamol, which is consistent with previous studies (8, 14) . . Graphs display means Ϯ standard error of mean. *P Ͻ 0.05 for dyspnea scores between control and asthma, **P Ͻ 0.05 for peak parameter between control and asthma for variable displayed on x-axis, and ***P Ͻ 0.05 for overall main group affect for IRV %TLC between control and asthma. fR, respiratory frequency; IRV, inspiratory reserve volume; TLC, total lung capacity; V E, minute ventilation; VT, tidal volume.
Limitations. While other studies have further characterized breathlessness associated with obstructive lung disease to be attributed to inspiratory effort (17, 18) , increased diaphragmatic muscle effort (6) , and increased ventilatory neural drive (6) , this study did not evaluate physiological measures of work of breathing, and further work is needed in this area.
Asthma is a heterogenous disease with various triggers, inflammatory phenotypes, and severity levels, and a larger scale study would be needed to address further differences in lung volumes and dyspnea responses to exercise between distinct phenotypes of asthma. The sensation of dyspnea is likely associated with asthma severity, and an even larger difference in dyspnea may be present in severe or uncontrolled asthma. The current study only included participants with controlled and partly controlled asthma, and to our knowledge, no data on exertional dyspnea and lung volume in uncontrolled asthma is currently available addressing this knowledge gap. Additionally, 7 of the 16 patients with asthma showed signs of EIB post cardiopulmonary exercise test; however, subanalyses did not reveal differences in dyspnea or measured lung volumes during exercise between those who did and did not experience EIB.
Recent work has documented sex differences in the ventilatory and sensory responses to exercise (5, 31). Our study purposely included an equal number of men and women in both groups to account for any potential differences between men and women. Future work examining sex differences in breathing mechanics is needed to better understand the pathophysiology of exertional dyspnea in asthma.
Neither the research participants nor the research staff were blinded to the administration of salbutamol in this study. As salbutamol is used to reverse bronchoconstriction, and thus reduce the sensations of breathlessness and chest tightness in asthma (1), the lack of blinding to the drug condition introduces a potential bias toward lower dyspnea and better exercise tolerance following ␤ 2 -agonist. However, as the administration of salbutamol did not affect operating lung volumes or dyspnea during incremental exercise, it is unlikely that the lack of change with ␤ 2 -agonist is explained by an absence of blinding.
In the current study, the occurrence of EFL was evaluated as the percent overlap of the tidal breath over the maximal flow volume loop achieved before exercise. This method of assessing EFL has inherent variability stemming from the occurrence of thoracic gas compression during the forced expiratory effort, EIB, or bronchodilation with exercise and potential human error during evaluation (23) .
Conclusion. Patients with asthma exhibit higher operating lung volumes (seen as low IC and IRV) than controls during exercise. The high operating lung volumes explain why patients with asthma experience increased exertional dyspnea and appear to be unaffected by salbutamol usage before exercise. To reduce physical activity avoidance in asthma, future research should examine approaches to normalize dynamic lung volumes and thus improve exertional dyspnea in asthma.
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